Infinity Med Spa Review: What Its GLP-1 Program Documents—and What Remains Unproven

Infinity Med Spa offers more than a medication name and a signup button: its public materials describe an initial assessment, possible laboratory testing, body-composition monitoring, monthly follow-up and nutritional support. For someone considering local weight-management care in Valencia or Santa Clarita, California, those are meaningful service details. But they answer a different question from whether a particular drug formulation has supporting clinical evidence—or whether this practice has demonstrated its own treatment outcomes.

This review separates those questions using public documentation consulted October 19, 2026. Infinity documents a GLP-1-related weight-management business, but its pages do not consistently identify the applicable prices, establish whether unbranded medications are approved products or compounded preparations, or identify the dispensing pharmacy. The strongest conclusion is therefore specific: the practice describes a substantial local care process, while several medication, financial and performance questions still require written clarification.

At a glance

Local practice: Infinity lists 25425 Orchard Village Road, Suite 180, Valencia, CA 91355, and advertises medically supervised weight management for Valencia and Santa Clarita.
Sources: [7] [5]
Medication selection: The practice says it may prescribe semaglutide, Ozempic or tirzepatide after reviewing a patient's history and goals; prescribing is not presented as automatic.
Sources: [5]
Conflicting program prices: General pages advertise semaglutide as low as $195 monthly and tirzepatide as low as $295 monthly; medication-specific pages advertise starting amounts of $395 and $595, respectively.
Sources: [5] [8] [12]
Separate entry charges: The medication-specific pages list $200 laboratory charges and a $400 NP/PA consultation despite advertising a complimentary initial consultation.
Sources: [8] [12]
Ozempic medication charge: Infinity separately lists an Ozempic pen at $1,300, with an estimated duration of approximately 12 weeks; the advertised monthly program fee is not an all-inclusive medication price.
Sources: [5] [9]

A documented local service, not a demonstrated outcome

Infinity presents itself as a Valencia med spa offering noninvasive cosmetic treatments alongside medical weight management. Its weight-loss page explicitly advertises medically supervised programs and GLP-1 injections for Santa Clarita and Valencia. That establishes the nature of the advertised service. It does not establish a nationwide prescribing network, a remote-care option or access outside California; those arrangements are not documented in the consulted materials.

The medication list includes semaglutide, Ozempic and tirzepatide, selected according to medical history and goals. Infinity says its clinicians determine candidacy during consultation and may prescribe medication depending on individual needs. This wording matters: the advertised consultation is an assessment, not a guarantee of a prescription. Complete clinical eligibility rules, including treatment-age requirements and contraindication screening, are not available in the reviewed text.

The provider also promotes individualized care and sustainable results. Those statements should remain attributed marketing claims rather than measured performance findings. The documentation reviewed here does not establish an Infinity-specific average weight change, treatment-completion rate or adverse-event rate. Our guide to what provider documents can prove explains this distinction: a detailed description of services can support confidence about what to ask for without independently validating the services' results.

Sources: [11] [7] [5]

What the consultation and clinical team are said to provide

Infinity describes an initial evaluation of medical history, lifestyle habits and nutritional status. It says laboratory testing may investigate hormonal imbalances, nutrient deficiencies or food sensitivities. The general Ozempic program information also requests bloodwork from the preceding 12 months. These statements do not clarify whether recent outside results replace the separately advertised laboratory charge, which tests are routinely required, or which are ordered only when clinically indicated.

The practice identifies Dr. Van J. Veloso as medical director and owner. Its staff biographies present Nicole Phillips as an FNP-BC whose specialties include weight management, and Kelly McCurdy as a PA-C with experience in family medicine, medical weight loss and aesthetic medicine. These are provider-published credential and experience statements, not independent licensing checks. A nurse practitioner or physician assistant is a clinician, but should not be described as a physician.

Infinity further says medical treatments are performed only by licensed doctors, nurse practitioners, physician assistants or registered nurses. That describes a broad staffing policy, not who will assess, prescribe for or follow a particular patient. The useful next question is role-specific: who conducts the complimentary consultation, who performs the separately priced clinical review, and which clinician remains responsible for medication questions between appointments?

Sources: [10] [5] [8] [12]

The medication identity is an important missing link

The semaglutide and tirzepatide pages describe instruction for once-weekly self-injection at home. This establishes the advertised route and administration setting, not the exact product dispensed. The consulted materials do not identify a dispensing pharmacy or establish whether the unbranded semaglutide and tirzepatide offerings are commercial products or compounded preparations. The Ozempic listing is more product-specific, but it does not resolve the identity of the other offerings.

That gap matters because FDA approval attaches to a specific product, not to a med spa or an ingredient name alone. FDA states that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy.

Before paying, request the exact product name, formulation, presentation and dispensing source in writing. Our explanation of approved medicines and compounded preparations separates those evidence questions. Infinity's general page also contains inconsistent terminology, using “Semaglutide Antagonist” in a heading while describing an agonist in the following text. That editing inconsistency is not proof of a prescribing error, but it reinforces the need for precise medication documentation.

Sources: [5] [8] [12] [1]

Conflicting prices make the actual package difficult to identify

Infinity's prices are public, but they are not reconciled across pages. The general program page advertises lower monthly amounts for semaglutide, tirzepatide and Ozempic than the medication-specific or membership pages. These are starting or “as low as” prices, not universal quotes. The differences should not be treated as a sale, a confirmed price increase or interchangeable packages without an explanation from the practice.

The semaglutide-specific page lists a $200 laboratory fee and a $400 consultation with an NP or PA to review results and the treatment plan. The tirzepatide-specific page lists the same amounts for bloodwork and an NP/PA review of results and medical history. A complimentary initial consultation therefore does not mean cost-free enrollment. The documentation does not consistently establish the complete first payment or whether the monthly semaglutide and tirzepatide charges fully include medication.

Ozempic has an explicitly separate $1,300 pen charge and an estimated pen duration of approximately 12 weeks. That estimate is not a personalized supply guarantee or a minimum commitment. Infinity also advertises 0% financing, but the reviewed text does not provide qualification rules or detailed financial terms. Obtain an itemized quote identifying the applicable page, billing interval, medication charge and laboratory requirements rather than selecting the lowest advertised figure.

Published price differences requiring confirmation
Offering	General program page	Other published terms
Injectable semaglutide program	As low as $195/month	Specific page: starting at $395/month, plus $200 laboratory testing and $400 NP/PA consultation; full medication inclusion unclear
Injectable tirzepatide program	As low as $295/month	Specific page: as low as $595/month, plus $200 bloodwork and $400 NP/PA consultation; full medication inclusion unclear
Ozempic program	As low as $195/month; separate $1,300 pen	Membership page: as low as $395/month, $200 bloodwork, $400 NP/PA consultation and $1,300 pen; estimated pen duration approximately 12 weeks
Semaglutide micro-dose membership	Starting at $195/month	Exact formulation, supplied quantity and complete inclusions require clarification
Tirzepatide micro-dose membership	Starting at $395/month	Specific page: starting at $295/month; applicable rate and complete package remain unclear

Sources: [5] [8] [12] [9] [6]

Follow-up is described more clearly than between-visit access

The $395 monthly semaglutide program describes one follow-up visit, weight and body-composition analysis, ongoing medication management as needed, and complimentary nutritional guidance with a diet plan. The $595 tirzepatide program similarly lists a monthly visit, body-composition analysis, individualized treatment adjustments and a diet plan. Infinity also describes metabolic testing and body-composition technology as tools for tracking progress and modifying a plan.

The general program description allows for dietary changes, exercise recommendations, behavioral therapy and procedures. The phrase “may include” is important: it does not establish that each component is routinely delivered or included in every fee. Ozempic follow-up is itself inconsistent, with one monthly check-in on the general page and two on the membership page. Patients should confirm the visit frequency and whether appointments involve the prescribing clinician.

The documentation does not establish response times for side-effect questions, urgent clinical access or missed-visit arrangements. NIDDK emphasizes that medication follow-up concerns tolerance and response, not simply continued payment. A practical discussion should therefore cover who reviews symptoms, how to contact that person and what happens if treatment is not tolerated. Our guide to clinical follow-up explains why a monthly appointment count alone cannot establish the adequacy of ongoing care.

Sources: [5] [8] [12] [9] [2]

Clinical trials cannot validate Infinity's micro-dose memberships

Infinity advertises a semaglutide micro-dose membership starting at $195 monthly. Its general page lists tirzepatide micro-dosing starting at $395 monthly, while the specific page lists $295. The tirzepatide page presents this as maintenance after initial weight loss. Those descriptions establish an advertised commercial offering; they do not establish a validated protocol, a clearly specified medication presentation or independently demonstrated maintenance outcomes.

The major trials in the consulted clinical context address different, defined questions. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight and a weight-related condition, without diabetes, over 68 weeks with lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight and a weight-related complication, excluding diabetes, over 72 weeks. Both were randomized trials, not evaluations of Infinity's services or its micro-dose memberships.

STEP 1 was funded by Novo Nordisk and SURMOUNT-1 by Eli Lilly; gastrointestinal adverse effects and treatment discontinuations were reported. Their findings cannot be transferred automatically to an unidentified preparation, a different regimen or an individual patient. Nor can separate trial results rank this clinic. Our guide to clinical trials versus provider performance explains why the evidence supporting a studied drug regimen is not evidence that every business advertising the ingredient achieves comparable outcomes.

Sources: [5] [12] [3] [4]

Contact paths are available; delivery responsibilities are not documented

Infinity provides a telephone number, 661-220-5102, a text number, 661-259-8100, and an online consultation request. It advertises free weight-management consultations Monday through Saturday. Its broader business hours are Monday through Friday, 9 a.m. to 6 p.m., and Saturday and Sunday, 10 a.m. to 5 p.m. Sunday opening hours should not be interpreted as confirmed Sunday weight-management consultation availability.

The described model combines local evaluation with instruction for home injections. It does not document whether medication is collected at the practice, obtained from an outside pharmacy or shipped. No carrier, dispatch timetable, delivery estimate or refrigeration protocol is established in the consulted materials. This is an information gap, not evidence that shipping is unavailable or that medication handling is inadequate.

Ask which organization dispenses the prescription, who supplies injection materials and whom to contact about a questionable product. If an injectable GLP-1 medication is shipped and arrives warm or with insufficient refrigeration, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. That is general regulatory guidance, not a finding about Infinity's deliveries. Language availability, including Spanish-language care, is also unconfirmed in the reviewed documentation.

Sources: [7] [5] [8] [12] [1]

Membership benefits do not substitute for treatment terms

Infinity advertises additional benefits for Ozempic and semaglutide program members: 20% off spa and laser services, 10% off injectables, 10% off skin-care products, and 20% off weight-loss or health supplements. These are ancillary commercial discounts, not evidence of medication effectiveness or necessary components of obesity care. Their presence also does not resolve which monthly fee applies or how long membership must continue.

The consulted materials do not establish minimum commitments, automatic renewal rules, advance-payment requirements, membership cancellation procedures, refunds or missed-appointment charges. Insurance acceptance, insurer billing and reimbursement arrangements are also unconfirmed. NIDDK notes that medication coverage varies by plan; coverage of a consultation and coverage of a prescription are separate questions. Nothing in the published starting prices should be treated as a confirmed insured out-of-pocket amount.

The website terms restrict site use to adults 18 and older, but that is not a complete treatment-age policy. They also select New York law and courts despite the listed California practice address; those website provisions do not establish a treatment agreement. Transactional texts can be stopped by replying STOP, with HELP or contactus@infinitymedspa.com available for assistance. Stopping messages does not cancel medical care, membership charges or any financial obligation.

Sources: [9] [13] [2]

Questions & answers

Is Infinity Med Spa's initial consultation really free?

Infinity advertises a complimentary initial consultation, including weight-management consultations Monday through Saturday. However, its semaglutide and tirzepatide pages separately list $200 laboratory charges and a $400 NP/PA consultation. Ask what the free meeting covers, when the paid clinical review occurs, and whether existing bloodwork can satisfy any testing requirement.

Sources: [5] [8] [12]

Which semaglutide or tirzepatide price should I expect?

The public pages do not establish one reconciled rate. General listings start at $195 monthly for semaglutide and $295 for tirzepatide, versus $395 and $595 on the specific medication pages. Request a dated, itemized quote stating the exact product, medication inclusion, laboratory charges, clinical consultation charge and ongoing billing interval before enrollment.

Sources: [5] [8] [12]

Does the Ozempic membership include the pen?

The pen is separately listed at $1,300, with an estimated duration of approximately 12 weeks. The general page advertises a program fee as low as $195 monthly, while the membership page lists $395 plus laboratory and consultation charges. Follow-up also differs between one and two monthly check-ins. Confirm the complete package rather than treating either monthly figure as all-inclusive.

Sources: [5] [9]

Does Infinity use compounded medication?

The reviewed documentation does not establish whether its unbranded semaglutide or tirzepatide is compounded or commercially manufactured, and it does not identify the dispensing pharmacy. Ask for the exact product and pharmacy. FDA recommends compounded drugs when an individual's medical needs cannot be met by an approved drug; compounded preparations are not FDA approved.

Sources: [8] [12] [1]

Can I use Infinity entirely online or outside California?

The documented service is centered on Valencia and Santa Clarita, with a published Valencia address and instructions for home injections. The consulted pages do not confirm a fully remote pathway, out-of-state care or medication shipping. Contact the practice about consultation requirements, where follow-up occurs and how medication reaches the patient; home administration alone does not establish telehealth availability.

Sources: [7] [5] [8] [12]

Does replying STOP cancel my weight-management membership?

No such membership-cancellation effect is documented. Infinity's terms say STOP cancels transactional SMS service. They do not provide the treatment-membership cancellation or refund rules in the reviewed text. Request those rules separately, including any notice deadline, renewal process and handling of medication already ordered. Message cancellation should not be used as a substitute for ending a paid service.

Sources: [13]

Our assessment

Infinity Med Spa documents a local weight-management service with clinical assessment, possible testing, home-injection instruction, monthly monitoring and nutritional support. Those details make its offering more concrete than a medication-only advertisement. They do not independently establish treatment outcomes, validate micro-dose claims or identify the evidence applicable to an unspecified preparation. The most consequential unresolved issues are the conflicting prices, exact medication and pharmacy, complete initial payment, between-visit clinical access, and membership exit terms. A prospective patient can use the free consultation to request a written medication description and itemized service agreement. Until those are available, the public materials support recognition of an advertised GLP-1 program—not a conclusion that its products, costs or results have been independently verified.

Visit Infinity Med Spa / Infinity MedSpa’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Infinity Med Spa Review: What Its GLP-1 Program Documents—and What Remains Unproven

At a glance

01A documented local service, not a demonstrated outcome

02What the consultation and clinical team are said to provide

03The medication identity is an important missing link

04Conflicting prices make the actual package difficult to identify

05Follow-up is described more clearly than between-visit access

06Clinical trials cannot validate Infinity's micro-dose memberships

07Contact paths are available; delivery responsibilities are not documented

08Membership benefits do not substitute for treatment terms